James Yang Liu - 20 Sep 2022 Form 3 Insider Report for Oncocyte Corp (OCX)

Role
Controller, PAO
Signature
/s/ James Liu
Issuer symbol
OCX
Transactions as of
20 Sep 2022
Net transactions value
$0
Form type
3
Filing time
22 Sep 2022, 17:38:35 UTC
Next filing
19 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCX Option to Purchase Common Stock 20 Sep 2022 Common Stock 10,000 $1.15 Direct F1
holding OCX Option to Purchase Common Stock 20 Sep 2022 Common Stock 2,260 $1.39 Direct F1
holding OCX Option to Purchase Common Stock 20 Sep 2022 Common Stock 75,000 $0.8870 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to Reporting Person's continued employment with Issuer on the applicable vesting dated.